In a regultory filing on the BSE, the city-based company said the US Food & Drug Administration (USFDA) has approved its 5mg and 10mg Memantine Hydrochloride tablets for treating moderate to severe Alzheimer's-type dementia.
"The US market for Memantine Hydrochloride tablets is about $60 million. The product will be manufactured at our flagship facility in Bengaluru and marketed by Strides Pharma Inc in the US at the earliest," said the filing.
As an integrated global pharmaceutical firm, Strides Shasun has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.
The company has manufacturing footprint with eight plants across three continents, including six US FDA-approved facilities and two for the emerging markets.
The company also has three R&D facilities in India, with global filing capabilities and a commercial footprint across 85 countries.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
About VDC
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.